Original article

Neelam Sharma^1,*, Anshul Jhanwar²


Affiliation:-
¹Assistant Professor, Department of Obstetrics & Gynecology, Jhalawar medical college, Jhalawar, Rajasthan, India
²Assistant Professor, Department of Pharmacology, Jhalawar medical college, Jhalawar, Rajasthan, India

The name of the department(s) and institution(s) to which the work should be attributed:
Department of Obstetrics & Gynecology, J.L.N. medical college, Ajmer, Rajasthan, India

Address reprint requests to
Dr. Anshul Jhanwar.
III/2,Doctor’s residence, Medical College Campus, Jhalawar, Rajasthan, India (Pin-326001)

Article citation:
Sharma N, Jhanwar A. To study the effect of Mifepristone-Misoprostol combination for first trimester abortion in cases with previously scarred uterus. J Pharm Biomed Sci 2014; 04(08):930-935. Available at www.jpbms.info

ABSTRACT
Introduction: In India to deal with unwanted pregnancy in the scarred uterus is thorny situation, since the caesarian section rate is increasing. Although most widely used method for terminating pregnancy is dilatation and evacuation but it increases morbidity and mortality by causing uterine perforation, serious hemorrhage and shock. Therefore medical abortion offers an advantageous alternative to surgical abortion.
Material and methods: Total one hundred and fifty patients were selected for the present prospective study and were divided randomly into two equal groups after fulfilling the inclusion and exclusion criteria. Both groups were given 200 mg Mifepristone followed by 800 µg Misoprostol after 48 hours. Group 1 consist of patients with previously scarred uterus. Group 2 consisted of patients with previously non-scarred uterus.
Results: Mean period of gestation in group 1 was 43.48 days and in group 2 was 43.81 days. Mean gravidity in group 1 was 3.24 and in group 2 was 3.17.Mean parity in group 1 was 2.2 while in group 2 was 2.14.Efficacy of procedure which was determined by the number of complete abortions in the group (92% in group 1 and 93.3% in group2.Minor side effects were seen in 21 % patients of group 1 as compared to 28% in group 2.
Conclusion: Both the groups who underwent medical abortion with mifepristone-misoprostol combination were found to be comparable in terms of efficacy, safety and acceptability for termination of pregnancy of gestational age upto 49 days.


KEYWORDS: Mifepristone, Misoprostol, Scarred uterus, Lower segment cesarean section. 


REFERENCES

1.Norman JE et al. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet 1991; 338:1233-1236.
2.Abraham Debby et al. Mid trimester abortion in patients with a previous uterine scar. European Journal of Obst & Gyne 2003.
3.Maitre SC,Bouchard P,Spitz IM .Medical termination of pregnancy.N Engl.J Med 2000;342:946-56.
4.Wu Y,Medical progress in China-Family planning.Natl Med J China 1995;75(12):749-75.
5.Creinin MD. Medical abortion regimens. Historical contest and overview. Am J Obstet & Gynecol 2000; 183:53-59.
6.Belfort P,Pinotti JA,Eskes Tkab.Fertility,sterility and contraception. Caterton Hall, Carnforth, UK: The Parthenon Publishing Group.1989; 28-31.
7.Bygdeman M. Termination of pregnancy upto 8 or 9 weeks-Modern methods of inducing abortion. Black-well science:Oxford;1995:39-53
8.Sun H,Wu S,Xu H et. Al.The potential of Ru 486 for medical termination of pregnancy: An acceptability and feasibility study. J Repro Med (China). 1995; 4(3):749-75.
9.Coyaji K,Etul B,Krishna U,Otiv S, Ambardekar S,Bopardikar A: Mifepristone abortion outside the urban research hospital setting in India.Lancet,2001;357:120-22.
10.Brogden RN, Goa KL, Faulds D. Mifepristone: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1993; 45:384-409.
11.Renee M, Hart S. Mifepristone: Annuals of pharmacotherapy 2001;35:707-15.
12.Robbins A,Spitz IM. Mifepristone clinical pharmacology. Clin Obstet Gynecol 1996;39:436-50.
13.Berghella V,Airoldi J. Misoprostol for first trimester pregnancy termination in women with prior cesarean;a systemic review. BJOG;May 2009.
14.Muhammad Fawzy. Mid trimester abortion using vaginal misoprostol for women with 3 or more prior cesarean deliveries. JJOG 2010 March.
15.Premila W,Prabath T. Factors affecting outcome of early medical abortion: A review of 4132 consecutive cases; BJOG: Nov 2002;109:1281-89.
16.J Xu, Chen H. Termination of early pregnancy in scarred uterus with mifepristone and misoprostol. IJOG.72 (2001):245-51.


Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patients and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.

Disclosure forms provided by the authors are available with the full text of this article at jpbms.info


Copyright © 2014 Sharma N, Jhanwar A. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Research article

Reyadh Jassim Abbas^1,*,May Al- Sabbagh¹, Dr Hassan Mohammed Abbas Altemmi², Dr Monewer³


Affiliation:-
¹Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad Iraqi
²Ph.D Clinical Pharmacy, Medical City Baghdad, Baghdad Iraq, 3MSC Oncology Medical City Baghdad, Iraq

The name of the department(s) and institution(s) to which the work should be attributed:
1Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad Iraqi

Address reprint requests to
Reyadh Jassim Abbas
Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad Iraqi 

Article citation:
Abbas RJ, Sabbagh-Al M, Altemmi Abaas HM, Monewer. The possible protective effect of melatonin in Iraqi breast cancer patients taking chemotherapy. J Pharm Biomed Sci. 2014; 04(11):1001-1006. Available at www.jpbms.info

ABSTRACT
Breast cancer is the most common cancer that lead to death in the world. The most common type of breast cancer is ductal carcinoma. Chemotherapy that used in the treatment of breast cancer is associated with adverse effects like cardio toxicity, especially with doxorubicin use, due to increase free radical formation like reactive oxygen species. To evaluate the protective effect of melatonin in Iraq breast cancer taking chemotherapy, 40 volunteers, 10 normal subjects served as control, 30 volunteers were divided into two groups randomly first 10 patient named group A taking only chemotherapy without melatonin. The second 20 patient named group B taking melatonin + chemotherapy. In the  current study, we measured serum malondialdehyde (MDA), liver function test (ALT, AST and TSB) and cardiac enzyme (CPK and LDH). The results showed that chemo therapy increase serum MDA, AIT, AST, CPK, LDH and reduction in serum TSB. Patients who taking extra supplement with melatonin (group B) showed normalized of these biochemical parameters. Melatonin has a role in protecting against toxicity that produced by chemotherapy.


KEYWORDS: Breast cancer; Chemotherapy; melatonin.

REFERENCES
1.American cancer society . Breast cancer . Fact and Figure 2009. American cancer society, Atlanta, GA2009.
2.Iraq cancer registry, 2010,p28.
3.Wood, WC  et at. Malignant tumor of breast in ;devitant,Hellman editor.Cancer principle and practice of oncology 7th edition , Philadelphia Pa. Lippincott william and Wilkins, pp77-1415.
4.Chu, E et al . Cancer chemotherapy.In; Katzung BG,editor. Basic and clinical pharmacology, 9th edition . Mc Graw-Hill, pp: 898-930.
5.Stefulj J et al. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J Pineal Res. 2001;30:243–247.
6.Ackermann K et al. Melatonin synthesis in the human pineal gland .BMC neuroscience. 2007; 8supp1:p2.
7.Pieri C. Melatonin peroxyl radical scavenger more effective than vit. E Life sci. 55(15): PL 271-6.
8.Reitman and frankel. As cited by Bio Merieux kit (france). Am J Clin Path.1957;28:56 .
9.Tietz N.W. text book of clinical chemistry 3rd ed. (1999):1133-1137.
10.Buege, JA, Austa SD. Method enzymol. 1978;51:302-310.
11.Sharhar S. et al. Antioxidant intake and status, and oxidative stress in relation to breast cancer risk: A case-control study. Asian Pac. J. Cancer Prev. 2008;9:343–349.
12.Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1996;313:17-29.
13.A.Nath et al. Elevated lipid peroxidation in breast cancer patients, Journal of pharmacy and biological sciences (JPBS),2001;9(4):17-21.
14.Shaoyu Zhou,et al. Doxorubicin–induce persistent oxidative stress to cardiac myocytes.2001;121:(3):151-157.
15.Ganiyu Oboh et al . Cyclophosphamide- induced oxidative stress in brain. Experimental and Toxicologic Pathology.2014;66(8):351-406.
16.Satoshi Numazawa et al. Possible Involvement of Oxidative Stress in 5-Fluorouracil-Mediated myelosuppression in mice. Basic & Clinical Pharmacology & Toxicology.2011;108(1):40–45.
17.Qi W, Reiter RJ, Tan DX, et al. Inhibitory effects of melatonin on ferric nitrilotriacetate-induced lipid peroxidation and oxidative DNAdamage in the rat kidney. Toxicology.1999;139:81–91.
18.Bateman JR, et al. 5-Fluorouracil given once weekly: comparison of intravenous and oral administration. Cancer. 1971;28:907-913.6
19.Paul D. King et al.Hepatotoxicity of Chemotherapy, The Oncologist.2001;6:162-176.p163.
20.Meredith MJ, Reed DJ. Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by Adriamycin and 1,3 chloroethyl-nitrosurea (BCNU). Biochem Pharmacol 1983;32:1383-1388.
21.Deepa PR, Varalakshmi P. Protective effect of low molecular weight heparin on oxidative injury and cellular abnormalities in adriamycin-induced cardiac and hepatic toxicity. Chemico-Biological Interactions. 2003;146:201-210.
22.Dr. Mustafa Ghazi Alabbassi. Melatonin Ameliorates Hepatic Damage Induced by Cyclophosphamide in rat.
23.Bahir Abdul Razzaq Mshemish et al . Effect of Silymarin against CAF protocol Hepatotoxicity, AJPS, 2011, Vol. 9, No.1.
24.Khalid A Al-Khazragi FRCP. Studying the Effect of Silymarin Against Hepatotoxicity Induced by CAF Protocol in Breast Cancer Women. Iraqi Medical Journal , Volume 56, Number 2, December 2010, ISSN 0304-4564.
25.Kamal Adel Amin,et al . Impact of Breast Cancer and Combination Chemotherapy on Oxidative Stress, Hepatic and Cardiac Markers, Sep 2012:15(3);306-312.
26.Ayça Bilgino?lu, M.D et al. Protective effect of melatonin on adriamycin-induced cardiotoxicity in rats. Arch Turk Soc Cardiol 2014; 42(3):265-273.
27.Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. http://www.nlm.nih.gov. Drug Saf. 2000 Apr;22(4):263-170.


Source of support: None

Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.


Copyright © 2014 Abbas RJ, Sabbagh-Al M, Altemmi Abaas HM, Monewer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review  article

Preetinder Singh^1,*.,MDS, Ayushi Gandotra².,BDS


Affiliation:-
¹Associate Professor (Periodontology and Oral Implantology) SDD Hospital and Dental College, Barwala, Panchkula (Haryana), India
²Research Associate, Private Practice, Chandigarh,India

The name of the department(s) and institution(s) to which the work should be attributed:
Periodontology and Oral Implantology, SDD Hospital and Dental College, Barwala, Panchkula (Haryana), India

Address reprint requests to
Dr. Preetinder Singh, MDS
Associate Professor (Periodontology and Oral Implantology) SDD Hospital and Dental College, Barwala, Panchkula(Haryana), India

Article citation:
Singh P, Gandotra A. Strategic occupational hazards affecting dental profession and its management: A review. J Pharm Biomed Sci. 2014; 04(11):995-1000. Available at www.jpbms.info

ABSTRACT
Occupational diseases are diseases arising from or out of activity in the workplace. It is resulting from exposure to physical, chemical, biological, psychosocial or ergonomics factors in the workplace. The presence of these factors in the workplace is essential for occupational diseases to occur; e.g.,exposure to lead in the workplace will leads to lead poisoning, and presence of silica in the workplace will cause silicosis. It must be recognized, however, that other factors, such as individual susceptibility, characteristics of exposure to those substances (example duration of exposure, concentration of substance, and condition of the substance) does have a role in the developing of occupational diseases. Occupational diseases of dentistry have, in general, received scant attention. The chief cause of this is lack of awareness among occupational dental physicians. Exposure to various chemical substances is one of the causes of occupation-related dental disorders. The present review aims to focus the attention of dental physicians towards this important problem.

KEYWORDS: occupational hazards; dentistry; biohazards; occupational diseases.


REFERENCES
1.Scott, S., De Rossi, D.M.D., Martin, S., Greenberg, D.D.S.: Intraoral contact allergy: a literature review and case reports, J. Am. Dent. Assoc., Vol. 129, pp. 14351-1441, 1998.
2.Guin, J.D.: Eyelid dermatitis from methacrylates used for nail enhacement. Contact Dermatitis, Vol. 39,pp. 312-313, 1998.
3.Fowler, J.F.: Late patch test reaction to acrylates in a dental worker, Am. J. Contact Dermat., Vol. 10, pp.224-225, 1999.
4.Lonnroth, E.C., Shahnavaz, H.: Use of polymer materials in dental clinics. Swed. Dent. J., Vol. 21, pp.149-150, 1997.
5.Bentley CD, Burkhart NW, Crawford JJ: Evaluating spatter and aerosol contamination during dental procedures. J Am Dent Assoc. 1994; 125:579-584.
6.Nimmo A, Werley MS, Martin JS, Tansy MF: Particulate inhalation during the removal of amalgam restorations. J Prosthet Dent. 1990;63:228-233.
7.Lan, Fu JS. Undue absorption of lead among children. A new look at an  old problem. New Eng J Med. 1972; 266: 702-10.
8.International Lobour Organization (ILO). Encyclopedia of occupational health and safety. 3rd ed. Geneva: ILO. 1983;1408-10.
9.Johansson AK. On dental erosion and associated factors. Swed Dent J  Suppl. 2002;1–77.
10.Darby ML, Walsh MM, editors. Dental hygiene theory and practice. 1st ed.  Philadelphia; WB Saynders Company. 1994.  p. 335-365.
11.Charpin D, Vervolet D: Epidemiology of immediate-type allergic reactions to latex. Clin Rev Allergy 1993, 11, 385-390.
12.Fisher AA: Contact urticaria and anaphylactoid reaction due to cornstarch surgical glove powder.  Contact Dermatitis. 1987;16:244-245.
13.Turjanamaa K, Alenius H, Mäkinen-Kiljunen S, Reunala T, Palosuo T: Natural rubber latex allergy. Allergy. 1996;51:593-602.
14.Tarlo SM, Sussman G, Contala A, Swanson MC: Control of  airborne latex by use of powder-free gloves.  J Allergy Clin Immunol1994, 93, 985-989.
15.Pretorius, E., Bester, M.J.: What every healt worker should know: the allergic potentional of surgical gloves. Southern African Journal of Epidemiology and Infection, Vol. 15, pp. 43-45, 2000.
16.Rustemayer, T., de Groot, J., von Blomberg, B.M.: Cross-reactivity paternsof contact-sensitizing methacrylates, Toxikology & Applied Pharmacology., Vol. 148, pp. 83-90, 1998.
17.Kanerva, L., Estalender, T., Jolanki, R., Alanko, K.: False-negative patch test reactions due to a lower concentration of a patch test substances then declared, Contact Dermatitis, Vol. 42, pp. 289-291, 2000.
18.Davis MS: Variations in patients’ compliance with doctors’ orders: analysis of congruence between survey responses and results of empirical investigations. J Med Educ 1966; 41:1037-1048.
19.Hulka BS, Cassel JC, Kupper LL, Burdette JA: Communication, compliance, and concordance between physicians and patients with prescribed medications. Am J Public Health 1976, 66, 847-853.
20.Turgut R, Krüger W: Psychosozialer Ansatz für die Motiveerung  zu praventivem Zahngesundheitsverhalten. Dtsch Zahnarztl Z 1982;37: 569-571.
21.Corah NL, O’Shea RM, Bissell GD: The dentist - patient relationship: perceptions by patients of dentist behavior in relation to satisfaction ond anxiety. J Am Dent Assoc. 1985;111(3):443-446.
22.Corah NL, O’Shea RM, Bissell GD: The dentist - patient relationship: mutual perceptions and behaviours. J Am Dent Assoc 1986;113(2):253-255.
23.Gale EN, Carlsson SG, Eriksson A, Jontell M: Effects of dentist’s behavior on patient’s attitudes. J Am Dent Assoc 1984, 109, 3, 444-446.
24.Simon JF, Peltier B, Chambers D, Dower J: Dentists troubled by the administration of anesthetic injections: long-term stresses and effects. Quintessence Int 1994, 25, 641-646.
25.Rankin J, Harris M: A comparision of stress and coping in male and female dentists. J Dent Pract Admin 1990, 7, 166-172.
26.Lussi A, Hellwig E, Zero D, Jaeggi T. Erosive tooth wear: diagnosis, risk factors and
prevention. Am J Dent. 2006 Dec;19(6):319-25.
27.Zero DT, Lussi A. Erosion--chemical and biological factors of importance to the dental practitioner. Int Dent J. 2005;55(4 Suppl 1):285-90.
28.Meurman JH, ten Cate JM. Pathogenesis and modifying factors of dental erosion. Eur J Oral Sci. 1996 Apr;104(2(Pt 2)):199-206.
29.Vanuspong W, Eisenburger M, Addy M. Cervical tooth wear and sensitivity: erosion,softening and rehardening of dentine; effects of pH, time and ultrasonication. J Clin Periodontol. 2002 Apr;29(4):351-7.
30.Jarvinen V, Rytomaa I, Meurman JH. Location of dental erosion in a referred population. Caries Res. 1992;26(5):391-6.
31.Rundcrantz BL, Johnsson B, Moritz U: Cervical pain and discomfort among in dentist. Epidemiological, clinical and therapeutic aspects. Part 1. A survey of pain and discomfort. Swed Dent J. 1990;14:71-80.
32.Rundcrantz BL, Johnsson B, Moritz U: Pain and discomfort in the musculoskeletal system among dentists. A prospective study. Swed Dent J. 1991;15: 219-228.
33.Rundcrantz BL, Johnsson B, Moritz U, Roxendal G: Cervicobrachial disorders in dentists. A comparison between two kinds of physiotherapeutic interventions. Scand J Rehabil Med. 1991;23:11-17.
34.Milerad E, Ekenvall L: Symptoms of the neck and upper exteremities in dentitists. Scand J Work Environ Health 1990;16:129-134.
35.Ostrem CT: Carpal tunnel syndrome. A look at causes, symptoms, remedies. Dent Teamwork 1996; 9:11-15.
36.Best Practice Guidelines for Occupational Safety and Health in DENTAL THERAPY PRACTICE, Auckland Regional Dental Service, Waitemata District Health Board, August 2001.


Source of support: None

Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.

Copyright © 2014 Singh P, Gandotra A. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review article

Mukund Joshi^1,*, Kuldip Singh Sodhi², Rajesh Pandey², Jasbir Singh², Subhash Goyal³


Affiliation:-
¹(MSc Medical Biochemistry),Department of Biochemistry,MMIMSR, Mullana, Ambala, Haryana, India.
²Professor,Department of Biochemistry,MMIMSR, Mullana, Ambala, Haryana, India.
³Professor, Department of Surgery, MMIMSR, Mullana, Ambala, Haryana, India

The name of the department(s) and institution(s) to which the work should be attributed:
Department of Biochemistry, MMIMSR, Mullana, Ambala, Haryana, India

Address reprint requests to
Mukund Joshi.
Department of Biochemistry,
MMIMSR, Mullana, Ambala, Haryana, India

Article citation:
Joshi M, Sodhi KS, Pandey R, Singh J, Goyal S. Serum uric acid and Cardiovascular disease. J Pharm Biomed Sci. 2014; 04(11):972-983. Available at www.jpbms.info

ABSTRACT
A substantial body of epidemiological and experimental evidence suggests the significance of serum uric acid as an important and independent risk factor of cardiovascular and renal diseases especially in patients with diabetes mellitus, hypertension or heart failure. Elevated serum uric acid is highly predictive of mortality in patients with heart failure or coronary artery disease and of cardiovascular events in patients with diabetes. Moreover patients with hypertension and hyperuricemia have a 3- to 5-fold increased risk of experiencing coronary artery disease or cerebrovascular disease compared with patients with normal uric acid levels. Although the mechanisms by which uric acid may play pathogenetic role in cardiovascular disease is unclear. Hyperuricemia is associated with deleterious effects on endothelial dysfunction, oxidative metabolism, platelet adhesiveness, hemorheology, and aggregation. Xanthine oxidase inhibitors (e.g., allopurinol) or a variety of uricosuric agents (e.g., probenecid, sulfinpyrazone, benzbromarone, and benziodarone) can lower elevated uric acid levels but it is unknown whether these agents reversibly impact cardiovascular outcomes. Hyperuricemia will become then a meaningful target for the prevention and treatment of cardiovascular disease. Overall, serum uric acid may be a powerful tool to help stratify risk for cardiovascular disease. At the very least, it should be carefully considered when evaluating overall cardiovascular risk.

KEYWORDS: Hypertension; uric acid; gout; allopurinol; coronary heart disease.

REFERENCES
1.Skak-Nielsen H. Torp-Pedersen C, Finer N, Caterson ID, Van Gaal L, James WP,  et al. Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. PLoS One. 2013; 8(3): e59121.
2.Emmerson BT. The management of gout. N Engl J Med. 1996; 334(7): 445-51.
3.Steele TH. Hyperuricemic nephropathies. Nephron. 1999; 81(1): 45-9
4.Yeldandi AV, Patel YD, Liao M, Kao FT, Rao MS, Reddy JK, et al. Localization of the human urate oxidase gene (UOX) to 1p22. Cytogenet Cell Genet. 1992; 61(2): 121-2.
5.Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992; 34(1): 78-84.
6.Kohn PM, Prozan GB. Hyperuricemia; relationship to hypercholesteremia and acute myocardial infarction. J Am Med Assoc. 1959; 170(16): 1909-12.
7.Beard JT 2nd. Serum uric acid and coronary heart disease. Am Heart J. 1983; 106(2): 397-400.
8.Torun M, Yardim S, Simsek B, Burgaz S. Serum uric acid levels in cardiovascular diseases. J Clin Pharm Ther. 1998; 23(1): 25-9.
9.Waring WS, Webb DJ, Maxwell SR. Uric acid as a risk factor for cardiovascular disease. QJM. 2000a; 93(11): 707-13.
10.Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999; 34(1): 144-50.
11.Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension. Lancet. 1998; 352(9129): 670-1.
12.Liese AD, Hense HW, Löwel H, Döring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology. 1999; 10(4): 391-7
13.Bengtsson C, Lapidus L, Stendahl C, Waldenström J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand. 1988; 224(6): 549-55
14.Lehto S, Niskanen L, Rönnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke. 1998; 29(3): 635-9.
15.Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart. 1997; 78(2): 147-53.
16.Coronaty heart project research group; Serum uric acid: its association with other risk factors and with mortality in coronary heart disease. J Chronic Dis. 1976; 29(9): 557-69.
17.Reunanen A, Takkunen H, Knekt P, Aromaa A. Hyperuricemia as a risk factor for cardiovascular mortality. Acta Med Scand Suppl. 1982; 668: 49-59.
18.Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999; 131(1): 7-13.
19.Iribarren C, Folsom AR, Eckfeldt JH, McGovern PG, Nieto FJ. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis Risk in Communities. Ann Epidemiol. 1996; 6(4): 331-40.
20.Reed DM, MacLean CJ, Hayashi T. Predictors of atherosclerosis in the Honolulu Heart Program. I. Biologic, dietary, and lifestyle characteristics. Am J Epidemiol. 1987; 126(2): 214-25.
21.Ames BN, Cathcart R, Schwiers E, and Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci 1981; 78: 6858–62.
22.Davies KJ, Sevanian A, Muakkassah-Kelly SF, and Hochstein P. Uric acidiron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J .1986; 235:747–754.
23.Nieto FJ, Iribarren C, Gross MD, Comstock GW, and Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000; 148:131–9.
24.De Scheerder IK, van de Kraay AM, Lamers JM, Koster JF, de Jong JW, Serruys PW. Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: potential mechanisms for free radical generation. Am J Cardiol 1991; 68: 392–5.
25.Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ., et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J. 1998; 19: 1814–22.
26.Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005; 16(12): 3553-62.
27.Johnson RJ., et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003; 41(6): 1183-90.
28.Costa F., et al. Intravascular source of adenosine during forearm ischemia in humans: implications for reactive hyperemia. Hypertension. 1999; 33(6): 1453-7
29.Raatikainen MJ, Peuhkurinen KJ, Hassinen IE. Contribution of endothelium and cardiomyocytes to hypoxia-induced adenosine release. J Mol Cell Cardiol. 1994; 26(8): 1069-80.
30.Fredholm BB, Sollevi A. Cardiovascular effects of adenosine. Clin Physiol. 1986; 6(1): 1-21
31.Kroll K, Bukowski TR, Schwartz LM, Knoepfler D, Bassingthwaighte JB Capillary endothelial transport of uric acid in guinea pig heart. Am J Physiol. 1992; 262(2 Pt 2): H420-31.
32.Castelli P, Condemi AM, Brambillasca C, Fundarò P, Botta M, Lemma M, Vanelli P, Santoli C, Gatti S, Riva E Improvement of cardiac function by allopurinol in patients undergoing cardiac surgery. J Cardiovasc Pharmacol. 1995; 25(1): 119-25.
33.Kogure K, Ishizaki M, Nemoto M, Kuwano H, Tatemoto K, Maruyama Y, et al. Evaluation of serum uric acid changes in different forms of hepatic vascular inflow occlusion in human liver surgeries. Life Sci. 1999; 64(5): 305-13.
34.Mathru M, Dries DJ, Barnes L, Sukhani R, Rooney MW. Tourniquet induced exsanquination in patients requiring lower limb surgery. An ischemia reperfusion model of oxidant and anti oxidant metabolism. Anesthesiology. 1996; 84:14-22
35.Anker SD, Leyva F, Poole-Wilson PA, Kox WJ, Stevenson JC, Coats AJ. Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart. 1997; 78(1): 39-43.
36.Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JM. Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin Exp Pharmacol Physiol. 1998; 25(3-4): 175-84.
37.Modan M, Halkin H. Hyperinsulinemia or increased  sympathetic drive as  links  for obesity and hypertension. Diabetes Care. 1991; 14(6): 470-87.
38.Zweier JL, Kuppusamy P, Lutty GA. Measurement of endothelial cell free radical generation: evidence for acentral mechanism of free radical injuryin postischemic tissues. Proc Natl AcadSci. 1988; 85: 4046-50
39.Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction and vasoconstriction. Kidney Int. 2005; 67:1739-42
40.Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD., et al.  Uric acid and inflammatory markers. Eur Heart J. 2006; 27: 1174-81.
41.Ruggiero C, Cherubini A, Miller E, Maggio M, Najjar SS, Lauretani F. et al. Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years. Am J Cardiol. 2007; 100: 115-121
42.Iliesiu A, Campeanu A, Dusceac D Serum uric acid and cardiovascular disease. Maedica (Buchar). 2010; 5(3): 186-92.
43.Hozawa A, Folsom AR, Ibrahim H, Nieto FJ, Rosamond WD, Shahar E, et al. Serum uric acid and risk of ischemic stroke: the ARIC study. Atherosclerosis. 2006; 187:401-407.
44.Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006; 54: 2688-2696.
45.Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric Acid and risk of myocardial infarction, stroke and congestive heart failure in 417734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Journal of Internal Medicine. 2009; 226: 558-570.
46.Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, et al. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens.1994; 8: 677–81.
47.Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980; 93: 817-821.
48.Puig JG and Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens.1999; 17: 869-72.
49.Fried HP, Till GO, Trentz O, Ward PA. Role of oxygen radicals in tourniquet related ischemia-reperfusion injury of human patients. Klin Wochenschr. 1991; 69: 1109–12.
50.Feig DI, Kang DH, Johnson RG. Uric acid and Cardiovascular Risk, N Engl J Med. 2008; 359: 1811-1821.
51.Lee JE, Kim YG, Choi YO. Serum uric acid Is Associated with Microalbuminuria in Prehypertension. Hypertension. 2006; 47: 962-967.
52.Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal independent mechanism. Hypertension. 2001; 38: 1101-06.
53.M azzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism Am J Physiol Renal Physiol. 2002; 282: 991-997.
54.Watanabe S., Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, et al . Uric acid, hominoid evolution and the pathogenesis of salt-sensitivity. Hypertension. 2002; 40: 355-360
55.Sundström J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence in the Framingham Heart Study. Hypertension. 2005; 45: 28-33.
56.Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and Incidence of Hypertension Among Men Without Metabolic Syndrome. Hypertension. 2007; 49: 298-303.
57.Feig DI, Johnson RJ. Hyperuricemia in childhood essential hypertension. Hypertension. 2003; 42: 247-252.
58.Alper AB Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL. Childhood Uric Acid Predicts Adult Blood Pressure: The Bogalusa Heart Study. Hypertension. 2005; 45: 34-38.
59.I Feig, B Soletsky, RJ Johnson. Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential Hypertension: A Randomized Trial. JAMA. 2008; 300(8): 924-32.
60.Hoeper MM, Hohlfeld JM, Fabel H. Hyperuricaemia in patients with right or left heart failure. Eur Respir J. 1999; 13: 682-685.
61.Campeanu A, Iliesiu A, Nistorescu D. Serum concentration of uric acid in patients hospitalized with chronic heart failure. Heart Failure Congress, Poster Session Berlin. 2010.
62.Lainscak M, von Haehling S, Anker SD. Natriuretic peptides and other biomarkers in chronic heart failure: From BNP, NT-proBNP, and MR-proANP to routine biochemical markers. International Journal of Cardiology. 2009; 3: 303-311.
63.Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, et al. Uric acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging. Circulation. 2003; 107: 1991-97.
64.Pascual-Figal DA, Hurtado-Martínez JA, Redondo B, Antolinos MJ, Ruiperez JA, Valdes M. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail. 2007; 9: 518-524
65.Alimonda AL, Núñez J, Núñez E, Husser O, Sanchis J, Bodí V, Miñana G, et al. Hyperuricemia in acute heart failure. More than a simple spectator? European Journal of Internal Medicine. 2009; 20: 74-9.
66.Ekundayo OJ, Dell'Italia LJ, Sanders PW, Arnett D, Aban I, Love TE, et al. Association between hyperuricemia and incident heart failure among older adults: Apropensity matched study. International Journal of Cardiology.  2010; 142: 279-87.
67.Krishnan E. Hyperuricemia and Incident Heart Failure. Circ Heart Fail. 2009; 2: 556-62
68.Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G. The paradoxical relationship between serum acid uric and cardiovascular disease. Clinica Chimica Acta. 2008; 392: 1-7.
69.Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004; 65: 1041-1049.
70.Athyros VG, Elisaf M, Papageorgiou AA .Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Am J Kidney Dis. 2004; 43: 589-599.
71.Farquharson CA, Butler R, Hill A. et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-226.
72.Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, et al. Impact of oxypurinol in patients with symptomatic heart failure. J Am Coll Cardiol. 2008; 51: 2301-2309.
73.Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, Stevenson JC, Coats AJ. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997; 8: 858–865.
74.Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973–79.
75.Mustard JF, Murphy EA, Ogryzlo MA. Smythe HA. Blood coagulation and platelet economy in subjects with primary gout. Can Med Assoc J. 1963; 89: 1207–11.
76.Johnson WD, Kayser KL, Brenowitz JB, Saedi SF. A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J. 1991; 121: 20–24.
77.Tabayashi K, Suzuki Y, Nagamine S, Ito Y, Sekino Y, Mohri H. A clinical trial of allopurinol (Zyloric) for myocardial protection. J Thorac Cardiovasc Surg. 1991; 101: 713–718.
78.Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104: 2407–2411.
79.Waring WS, Webb DJ, Maxwell SRJ. Effect of local hyperuricemia on endothelial function in the human forearm vascular bed. Br J Clin Pharmacol. 2000b; 49: 511.
80.Kanabrocki EL, Third JL, Ryan MD, Nemchausky BA, Shirazi P, Scheving LE, et al Circadian relationship of serum uric acid and nitric oxide. JAMA. 2000; 283: 2240–41.
81.Santos CXC, Anjos EI, Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys. 1999; 372: 285–294.
82.Abuja PM. Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett. 1999; 446: 305–8.
83.Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM., et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys. 2000; 376: 333-7.
84.Hink HU, Santanam N, Dikalov S, McCann L, Nguyen AD, Parthasarathy S,. et al. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol. 2002; 22: 1402–8.
85.Maples KR, Mason RP. Free radical metabolite of uric acid. J Biol Chem. 1988; 263: 1709-12.
86.Feig D I, Kang D H, Johnson R J. Uric Acid and Cardiovascular Risk. N Engl J Med. 2008 October 23; 359(17): 1811–1821.
87.George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114: 2508–16.
88.Waring WS, McKnight JA, Webb DJ, Maxwell SR. Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia. 2007; 50: 2572–9.


Source of support: None

Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.


Copyright © 2014 Joshi M, Sodhi KS, Pandey R, Singh J, Goyal S. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Original article

Shanta Nibedita Satpathy*


Affiliation:-
Associate Professor, Department of ENT, Hi-Tech Medical College, Bhubaneswar, Odisha, India

The name of the department(s) and institution(s) to which the work should be attributed:
Department of ENT, INHS Ashwini, Colaba Mumbai, Maharastra, India

Address reprint requests to
Dr. Shanta Nibedita Satpathy.
Department of ENT, Hi-Tech Medical College, Bhubaneswar, Odisha, India

Article citation:
Satpathy SN. Role of Immunotherapy: Histaglobulin in Allergic Rhinitis. J Pharm Biomed Sci. 2014; 04(11):967-971. Available at www.jpbms.info

ABSTRACT
Objective: The aim of our study was to improve the quality of life of Allergic Rhinitis patients by giving Histaglobulin injection. Otolaryngologists have been disappointed with the results of various modalities available for the treatment of allergic rhinitis. This problem can be solved with Histaglobulin.
Materials and methods: A study of 50 patients of allergic rhinitis in South Bombay was conducted in the department of ENT and Head and Neck Surgery in INHS Ashwini at Colaba for a period of 18 months. Histaglobulin was administered by subcutaneous injection in doses of 2 cc once a week for 3weeks and follow up was done for 40 weeks.
Results: The effectiveness of Histaglobulin was evaluated by detail history of clinical examination to assess the response to therapy. Twenty three (23) patients had complete response; twenty five (25) had fair response while two (2) patients had a poor response.
Conclusions: The results of Histaglobulin therapy was satisfactory. There was no adverse reaction following the therapy.

KEYWORDS: Allergic Rhinitis; Histaglobulin; Quality of Life.


REFERENCES
1.Parrot, J.L. Histaminolyse at histaminopesive: Actualities pharmacologiques 11th Ser PP. 233-257, Paris Masson 1958.
2.NormanPhilp S., Immunotherapy for nasal allergy, Journal of Allergy clinical Immunology pp.992-996, May 1988.
3.Gelfand, H. herald, cinder Jesus. Grant Sydney F. and Soiffer Maxwell: Evaluation of Histamine – Gammaglobulin in treatment of various allergic conditions, Annals of Allergy,1963;21:150-161.
4.Asokan N.N. and Sukumaran E.M., Gammaglobulin histamine complex in the treatment of allergic disorders of respiratory tract, the Indian Practitioner. 1982;35:171-176.
5.Borodin Y, Egerova Mezhcodava A, The use of Gammaglobulin and Histamine for treating Allergic disease, Rev. allergy ad appl. Immunology, 17.434, 1963.

Source of support: None

Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussing research work. There is no financial conflict with the subject matter discussed in the manuscript.

Copyright © 2014 Satpathy  SN. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.